Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Sequencing Therapies for mTNBC

October 23rd 2020

Standard of Care for BRCA+ mTNBC

October 23rd 2020

Testing for PD-L1 Expression in mTNBC

October 23rd 2020

KEYNOTE-355 Trial in mTNBC

October 23rd 2020

Standard of Care for Metastatic TNBC

October 23rd 2020

Current Trials for Treatment of Early Stage TNBC

October 23rd 2020

Emerging Data on Biomarkers in ES TNBC

October 23rd 2020

ICI-Based Therapy in TNBC: Immune-Related Adverse Events

October 23rd 2020

Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC

October 23rd 2020

Early Stage TNBC: Phase 3 IMpassion031 Study

October 23rd 2020

Key Trials in ICI-Based Therapy for Early Stage TNBC

October 23rd 2020

Role of pCR in Early Stage TNBC Management

October 23rd 2020

Standard of Care for Early-Stage TNBC

October 23rd 2020

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

O’Regan Weighs Escalation, De-Escalation Approaches in Early-Stage HER2+ Breast Cancer

October 21st 2020

In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer

Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer

October 21st 2020

New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Dr. Lwin on the Design of the LEAP-005 Trial in Pretreated Advanced Solid Tumors

October 20th 2020

Zarnie Lwin, MBBS, FRACP, discusses the design of the phase 2 LEAP-005 trial in previously treated patients with advanced solid tumors.

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

October 19th 2020

Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

FIP200 Deletion May Enhance Response to Immunotherapy in Breast Cancer

October 19th 2020

FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.